Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

Xing, Mingzhao; S. Alzahrani, Ali; A. Carson, Kathryn; Viola, David; Elisei, Rossella; Bendlová, Běla; Yip, Linwah; Mian, Caterina; Vianello, Federica; Michael Tuttle, R.; Robenshtok, Eyal; A. Fagin, James; Puxeddu, Efisio; Fugazzola, Laura; Czarniecka, Agnieszka; Jarząb, Barbara; J. O’Neill, Christine; Sywak, Mark; K. Lam, Alfred; Riesco‐Eizaguirre, Garcilaso; Santisteban, Pilar; Nakayama, Hirotaka; P. Tufano, Ralph; I. Pai, Sara; A. Zeiger, Martha; H. Westra, William; P. Clark, Douglas; Clifton‐Bligh, Roderick; Sidransky, David; W. Ladenson, Paul; Sýkorová, Vlasta

doi:10.1001/jama.2013.3190

Public

Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

Published in JAMA • Apr 9, 2013

Authors:

Mingzhao Xing

Ali S. Alzahrani

Kathryn A. Carson

Abstract

IMPORTANCE: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. OBJECTIVE: To investigate the relationship between BRAF V600E mutation and PTC-related mortality. DESIGN, SETTING, AND PARTICIPANTS: Retrospective...

Subject

Medicine

Interquartile range

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!